FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3110939034> ?p ?o ?g. }

• W3110939034 endingPage "659" @default.
• W3110939034 startingPage "645" @default.
• W3110939034 abstract "Therapeutic options in recurrent or metastasized vulvar squamous cell cancer (VSCC) not amenable to radiotherapy or radical surgery are limited. Evidence for the use of targeted therapies is sparse. All patients with VSCC treated at the Gynecological Cancer Center Hamburg-Eppendorf 20132019 were retrospectively evaluated for targeted therapeutic approaches. Furthermore, a MEDLINE, EMBASE, Web of Science, Scopus, and OVID database search was performed using the terms: vulvar cancer AND targeted therapy, erlotinib, EGFR, bevacizumab, VEGF, pembrolizumab, or immunotherapy. Twelve of 291 patients (4.1%) with VSCC received at least one targeted therapy at our institution. Previously, one or more platinum-based chemotherapy was applied to all patients [median 3.5 previous lines (range 25)]. In the erlotinib subgroup, two of five patients (40%) achieved stable disease (SD), while two patients (2/5, 40%) experienced partial response (PR). Treatment was given as monotherapy in second/third line for a median of 3.4 months (range 26 months). Bevacizumab (n=9) was given as maintenance therapy after platinum-based first-line chemotherapy (9/9); best response was complete response (CR) (n=2/9 22.2%). Median duration of treatment was 7 months (range 413 months) with two patients still under ongoing treatment. Best response in the pembrolizumab (n=3) subset was SD (n=1/3 33%). Treatment was given as monotherapy in second/third line for a median of 3.3 months (range 34 months). Nine of 12 patients (75%) experienced treatment-related adverse events (TRAEs), most commonly grade 1/2. Rapidly evolving antibody treatments have proven clinical benefit especially in HPV-driven tumor entities; however, clinical investigations in VSCC are still limited. These reported cases provide evidence for the clinical utility and feasibility while ensuring an acceptable safety profile." @default.
• W3110939034 created "2020-12-21" @default.
• W3110939034 creator A5022606829 @default.
• W3110939034 creator A5034204447 @default.
• W3110939034 creator A5040465251 @default.
• W3110939034 creator A5042711497 @default.
• W3110939034 creator A5055308254 @default.
• W3110939034 creator A5062360985 @default.
• W3110939034 creator A5069034017 @default.
• W3110939034 creator A5069415804 @default.
• W3110939034 creator A5071055386 @default.
• W3110939034 creator A5089567856 @default.
• W3110939034 date "2020-03-16" @default.
• W3110939034 modified "2023-10-17" @default.
• W3110939034 title "Targeted Therapeutic Approaches in Vulvar Squamous Cell Cancer (VSCC): Case Series and Review of the Literature" @default.
• W3110939034 cites W1546194081 @default.
• W3110939034 cites W1907135256 @default.
• W3110939034 cites W1940241680 @default.
• W3110939034 cites W1963487632 @default.
• W3110939034 cites W1992246743 @default.
• W3110939034 cites W2005943756 @default.
• W3110939034 cites W2012908535 @default.
• W3110939034 cites W2021103553 @default.
• W3110939034 cites W2028256854 @default.
• W3110939034 cites W2030071820 @default.
• W3110939034 cites W2043808543 @default.
• W3110939034 cites W2056370053 @default.
• W3110939034 cites W2059958002 @default.
• W3110939034 cites W2081153580 @default.
• W3110939034 cites W2081423951 @default.
• W3110939034 cites W2084196799 @default.
• W3110939034 cites W2089888164 @default.
• W3110939034 cites W2094956230 @default.
• W3110939034 cites W2097196133 @default.
• W3110939034 cites W2100756525 @default.
• W3110939034 cites W2106680950 @default.
• W3110939034 cites W2128228131 @default.
• W3110939034 cites W2128978912 @default.
• W3110939034 cites W2319610879 @default.
• W3110939034 cites W2320400231 @default.
• W3110939034 cites W2461675223 @default.
• W3110939034 cites W2468103096 @default.
• W3110939034 cites W2473877184 @default.
• W3110939034 cites W2474070100 @default.
• W3110939034 cites W2498001490 @default.
• W3110939034 cites W2498840633 @default.
• W3110939034 cites W2527905628 @default.
• W3110939034 cites W2739132742 @default.
• W3110939034 cites W2740572218 @default.
• W3110939034 cites W2742133220 @default.
• W3110939034 cites W2745112830 @default.
• W3110939034 cites W2763868559 @default.
• W3110939034 cites W2800348651 @default.
• W3110939034 cites W2883947000 @default.
• W3110939034 cites W2886377456 @default.
• W3110939034 cites W2904444972 @default.
• W3110939034 cites W2914335731 @default.
• W3110939034 cites W2925815206 @default.
• W3110939034 cites W2940170149 @default.
• W3110939034 cites W2947026438 @default.
• W3110939034 cites W2947080546 @default.
• W3110939034 cites W2970121740 @default.
• W3110939034 cites W2999417355 @default.
• W3110939034 cites W3019699550 @default.
• W3110939034 cites W4238953989 @default.
• W3110939034 cites W868181563 @default.
• W3110939034 cites W92798296 @default.
• W3110939034 doi "https://doi.org/10.3727/096504020x16076861118243" @default.
• W3110939034 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7962928" @default.
• W3110939034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33308371" @default.
• W3110939034 hasPublicationYear "2020" @default.
• W3110939034 type Work @default.
• W3110939034 sameAs 3110939034 @default.
• W3110939034 citedByCount "9" @default.
• W3110939034 countsByYear W31109390342021 @default.
• W3110939034 countsByYear W31109390342022 @default.
• W3110939034 countsByYear W31109390342023 @default.
• W3110939034 crossrefType "journal-article" @default.
• W3110939034 hasAuthorship W3110939034A5022606829 @default.
• W3110939034 hasAuthorship W3110939034A5034204447 @default.
• W3110939034 hasAuthorship W3110939034A5040465251 @default.
• W3110939034 hasAuthorship W3110939034A5042711497 @default.
• W3110939034 hasAuthorship W3110939034A5055308254 @default.
• W3110939034 hasAuthorship W3110939034A5062360985 @default.
• W3110939034 hasAuthorship W3110939034A5069034017 @default.
• W3110939034 hasAuthorship W3110939034A5069415804 @default.
• W3110939034 hasAuthorship W3110939034A5071055386 @default.
• W3110939034 hasAuthorship W3110939034A5089567856 @default.
• W3110939034 hasBestOaLocation W31109390341 @default.
• W3110939034 hasConcept C121608353 @default.
• W3110939034 hasConcept C126322002 @default.
• W3110939034 hasConcept C141071460 @default.
• W3110939034 hasConcept C143998085 @default.
• W3110939034 hasConcept C197934379 @default.
• W3110939034 hasConcept C2776694085 @default.
• W3110939034 hasConcept C2777701055 @default.
• W3110939034 hasConcept C2777802072 @default.
• W3110939034 hasConcept C2778087573 @default.

• next